Publication at First Faculty of Medicine |
2010
Abstract
Background: Human epidermal growth factor receptor 2 (HER2) overexpression increases the aggressiveness of breast cancer cells resulting in poorer prognosis. Patients with HER2-positive disease are less responsive to endocrine therapies.
Trastuzumab monotherapy results in objective responses in only similar to 15% of patients. Fulvestrant retains activity in cells overexpressing HER2 that are resistant to other endocrine treatments.
This retrospective study evaluated response to fulvestrant treatment among HER2-positive patients with advanced breast cancer (ABC).